FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on December 10, 2024, it received a notification (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Rule 5550(a)(2) (the “Bid Price Requirement”), and Nasdaq has determined to continue the listing of the Company’s Class A ordinary shares (“Class A Ordinary Shares”) on the Nasdaq Capital Market under the symbol “APLM.”
Read more at globenewswire.com